“liver-disease” Archives

in
Entry Author Date Location
CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage 08/04/20 San Francisco
Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More 07/17/20 National
Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More 06/19/20 National
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate 11/08/19 National
Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond 10/02/19 San Diego
Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38% 09/30/19 Raleigh Durham
Organovo Halts Liver Tissue R&D, Plans Restructuring to Cut Costs 08/07/19 San Diego
Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts 07/18/19 National
Conatus to Slash Staff, Consider Sale After NASH Trial Failures 06/25/19 San Diego
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan 05/02/19 Texas
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering 04/18/19 Texas
Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs 04/16/19 National
With New Data, Intercept On Track for First-Ever Approved NASH Drug 02/19/19 New York
San Antonio Life Science Business Acelity Cuts 260 Jobs in Texas, NC 02/11/19 Texas
Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs 11/07/18 San Diego
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future? 08/08/18 San Francisco
Exact Sciences, Mayo Clinic Share Data on DNA-Based Liver Cancer Test 06/06/18 Wisconsin
Arrowhead Plans Return to Clinic With New Study of Hep B Drug 02/16/18 Wisconsin
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Cirius Therapeutics Raises $40M to Expand Ongoing Liver Study 04/11/17 San Diego
With $20M, UCSD Spinout Jecure To Press New Attack On NASH 02/15/17 San Diego
Texas Roundup: HTC, Indigo, DEC, Rakesh Agrawal, Piko, & Top of 2016 01/10/17 Texas
Acelity Sells LifeCell Tissue Repair Unit to Allergan for $2.9B 12/20/16 Texas
Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease 05/28/16 New York
As Rivals Make News, Intercept Heads To Daylong Hearing For Liver Drug 04/06/16 New York
RaNA CEO Renaud Turns To A Former Backer To Lead $55M Series B 07/23/15 Boston
With IPO Expectations Reset (Again), Vital Therapies Begins Trading 04/17/14 San Diego
San Diego Life Sciences Roundup: Celladon, Halozyme, Zogenix, & More 04/11/14 San Diego
San Diego Life Sciences Roundup: Ignyta, Conatus, Liver Prize & More 12/06/13 San Diego
Page 1 of 2 next page »